Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-100-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New RDM0039H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Tissue extract, Whole blood, Cultural lysates (HEK, HeLa), Fibroblast 3T3 cells

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

6.25 – 0.2 amol/μl

Limit of Detection

0.065 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 3.4%

Inter-assay (Run-to-Run)

n = 5,
CV = 9.7%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-100-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology, Reproduction, Neurodegenerative disease


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

MicroRNA-100 (miR-100), located on chromosome 11 at 11q24.1, is a member of the miR-99 family. It is involved in regulating multiple cell processes, such as cell apoptosis, cell cycle, differentiation, proliferation, invasion and migration.

miR-100 was reported to enhance the chemosensitivity of various tumor cells to chemotherapeutics. miR-100–5p was the most prominent decreased miRNA in exosomes derived from lung cancer cells confer cisplatin (DDP) and the fold change of miR-100–5p in exosomes was larger than that in cells, which implied that this abnormal reverse concentration of miR-100–5p might play a vital role in communication between tumor cells. The decreased expression of miR-100 was wildly reported to be involved in drug resistance in various cancer patients. Increased hsa-mir-99b-3p expression level showed a tendency toward advanced tumor stages, and high levels of hsa-mir-100-5p expression were associated with extracapsular extension. While a high expression level of hsa-mir-99b-3p was associated with better survival, a high expression level of hsa-mir-100-5p was correlated with a poorer survival in oral squamous cell carcinoma OSCC.

Deregulation of miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in urothelial carcinoma of the bladder (UCB) patients with aggressive phenotype compared with nonaggressive subject. Six miRNAs were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p).

Five upregulated miRNAs (miR-122-5p, miR-125b-5p, miR-885-5p, miR-100-5p and miR-148a-3p) in CHB, cirrhosis and hepatocellular carcinoma (HCC) patients are potential biomarkers for chronic Hepatitis B (CHB) infection. Other studies showed that low expressions of miR-100-5p and miR-148a-3p were associated with gross vascular invasion (VI) and poor survival of patients after hepatic resection for HCC.

Gestational hypertension (GH), preeclampsia (PE) and fetal growth restriction (FGR) may predispose to later onset of cardiovascular/cerebrovascular diseases. PE and/or FGR with abnormal Doppler parameters demonstrated up-regulation of miR-100-5p, miR-125b-5p, miR-133a-3p, and miR-145-5p. The combination screening was superior over using individual microRNAs for patients with GH, PE regardless of the severity of the disease, severe PE and early PE. A cardiovascular risk at patients with late PE, PE and/or FGR with abnormal Doppler parameters was identified more accurately using the single microRNA only.

It was found that miR-100 in cerebrospinal fluid (CSF) from Alzheimer’s disease (AD) patients could serve as one of the reliable biomarkers to detect AD. MiR-99b-5p/100-5p has been found to promote cell apoptosis with the Amyloid β (Aβ) treatment. Dynamic change of miR-99b-5p/100-5p levels during Aβ-associated pathologies might be attributed to Aβ-induced endoplasmic reticulum stress (ER stress).

Summary References (11)

References to miR-100-5p

  • Denk J, Boelmans K, Siegismund C, Lassner D, Arlt S, Jahn H. MicroRNAProfiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease. PLoSOne. 2015 May 20;10(5):e0126423. doi: 10.1371/journal.pone.0126423. eCollection2015. PubMed PMID: 25992776; PubMed Central PMCID: PMC4439119. See more on PubMed
  • Hromadnikova I, Kotlabova K, Dvorakova L, Krofta L. Postpartum profiling ofmicroRNAs involved in pathogenesis of cardiovascular/cerebrovascular diseases in women exposed to pregnancy-related complications. Int J Cardiol. 2019 Sep15;291:158-167. doi: 10.1016/j.ijcard.2019.05.036. Epub 2019 May 21. PubMed PMID:31151766. See more on PubMed
  • Inamoto T, Uehara H, Akao Y, Ibuki N, Komura K, Takahara K, Takai T, Uchimoto T, Saito K, Tanda N, Yoshikawa Y, Minami K, Hirano H, Nomi H, Kato R, Hayashi T, Azuma H. A Panel of MicroRNA Signature as a Tool for Predicting Survival ofPatients with Urothelial Carcinoma of the Bladder. Dis Markers. 2018 Jun20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018. PubMed PMID:30026881; PubMed Central PMCID: PMC6031086. See more on PubMed
  • Jakob M, Mattes LM, Küffer S, Unger K, Hess J, Bertlich M, Haubner F, Ihler F,Canis M, Weiss BG, Kitz J. MicroRNA expression patterns in oral squamous cellcarcinoma: hsa-mir-99b-3p and hsa-mir-100-5p as novel prognostic markers for oralcancer. Head Neck. 2019 Oct;41(10):3499-3515. doi: 10.1002/hed.25866. Epub 2019Jul 29. PubMed PMID: 31355988. See more on PubMed
  • Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, Lim TKH, Goh GBB,Krishnamoorthy TL, Kumar R, Ng TP, Chong SS, Tan HH, Chung AYF, Ooi LLPJ, ChangJPE, Tan CK, Lee CGL. Circulating microRNAs as Potential Diagnostic andPrognostic Biomarkers in Hepatocellular Carcinoma. Sci Rep. 2019 Jul18;9(1):10464. doi: 10.1038/s41598-019-46872-8. PubMed PMID: 31320713; PubMedCentral PMCID: PMC6639394. See more on PubMed
  • Li C, Gao Y, Zhang K, Chen J, Han S, Feng B, Wang R, Chen L. Multiple Roles ofMicroRNA-100 in Human Cancer and its Therapeutic Potential. Cell Physiol Biochem.2015;37(6):2143-59. doi: 10.1159/000438572. Epub 2015 Nov 26. Review. PubMedPMID: 26606597. See more on PubMed
  • Luan Y, Zhang S, Zuo L, Zhou L. Overexpression of miR-100 inhibits cellproliferation, migration, and chemosensitivity in human glioblastoma throughFGFR3. Onco Targets Ther. 2015 Nov 17;8:3391-400. doi: 10.2147/OTT.S85677.eCollection 2015. PubMed PMID: 26604796; PubMed Central PMCID: PMC4655956. See more on PubMed
  • Luo J, Chen B, Ji XX, Zhou SW, Zheng D. Overexpression of miR-100 inhibitscancer growth, migration, and chemosensitivity in human NSCLC cells throughfibroblast growth factor receptor 3. Tumour Biol. 2015 Aug 28. [Epub ahead ofprint] PubMed PMID: 26314855. See more on PubMed
  • Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D, Feng J.Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatinresistance of recipient cells in exosomal miR-100-5p-dependent manner. Int JNanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection2017. PubMed PMID: 28553110; PubMed Central PMCID: PMC5439933. See more on PubMed
  • Song SK, Jung WY, Park SK, Chung CW, Park Y. Significantly differentexpression levels of microRNAs associated with vascular invasion inhepatocellular carcinoma and their prognostic significance after surgicalresection. PLoS One. 2019 Sep 12;14(9):e0216847. doi:10.1371/journal.pone.0216847. eCollection 2019. PubMed PMID: 31513595; PubMedCentral PMCID: PMC6742465. See more on PubMed
  • Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z, Fu L, Dong JT. MicroRNA 100sensitizes luminal A breast cancer cells to paclitaxel treatment in part bytargeting mTOR. Oncotarget. 2016 Feb 2;7(5):5702-14. doi:10.18632/oncotarget.6790. PubMed PMID: 26744318; PubMed Central PMCID:PMC4868715. See more on PubMed
Related Products Docs